Alpha-Synuclein Oligomers Interact with Metal Ions to Induce Oxidative Stress and Neuronal Death in Parkinson's Disease

Abstract Aims: Protein aggregation and oxidative stress are both key pathogenic processes in Parkinson's disease, although the mechanism by which misfolded proteins induce oxidative stress and neuronal death remains unknown. In this study, we describe how aggregation of alpha-synuclein (α-S) from its monomeric form to its soluble oligomeric state results in aberrant free radical production and neuronal toxicity. Results: We first demonstrate excessive free radical production in a human induced pluripotent stem-derived α-S triplication model at basal levels and on application of picomolar doses of β-sheet-rich α-S oligomers. We probed the effects of different structural species of α-S in wild-type rat neuronal cultures and show that both oligomeric and fibrillar forms of α-S are capable of generating free radical production, but that only the oligomeric form results in reduction of endogenous glutathione and subsequent neuronal toxicity. We dissected the mechanism of oligomer-induced free radical production and found that it was interestingly independent of several known cellular enzymatic sources. Innovation: The oligomer-induced reactive oxygen species (ROS) production was entirely dependent on the presence of free metal ions as addition of metal chelators was able to block oligomer-induced ROS production and prevent oligomer-induced neuronal death. Conclusion: Our findings further support the causative role of soluble amyloid oligomers in triggering neurodegeneration and shed light into the mechanisms by which these species cause neuronal damage, which, we show here, can be amenable to modulation through the use of metal chelation. Antioxid. Redox Signal. 24, 376–391.

[1]  H. Schmidt,et al.  Evolution of NADPH Oxidase Inhibitors: Selectivity and Mechanisms for Target Engagement. , 2015, Antioxidants & redox signaling.

[2]  D. Klenerman,et al.  Aggregated α-synuclein and complex I deficiency: exploration of their relationship in differentiated neurons , 2015, Cell Death and Disease.

[3]  C. Dobson,et al.  Structural characterization of toxic oligomers that are kinetically trapped during α-synuclein fibril formation , 2015, Proceedings of the National Academy of Sciences.

[4]  D. Klenerman,et al.  Lipid peroxidation is essential for α‐synuclein‐induced cell death , 2015, Journal of neurochemistry.

[5]  M. Walker,et al.  Seizure activity results in calcium- and mitochondria-independent ROS production via NADPH and xanthine oxidase activation , 2014, Cell Death and Disease.

[6]  DuhamelAlain,et al.  Targeting chelatable iron as a therapeutic modality in Parkinson's disease. , 2014 .

[7]  N. Wood,et al.  PINK1 deficiency in β-cells increases basal insulin secretion and improves glucose tolerance in mice , 2014, Open Biology.

[8]  S. Kovac,et al.  Lipid peroxidation is essential for phospholipase C activity and the inositol-trisphosphate-related Ca2+ signal , 2014, Journal of Cell Science.

[9]  David R. Brown α-Synuclein as a ferrireductase. , 2013, Biochemical Society transactions.

[10]  D. Surmeier,et al.  Calcium Entry and α-Synuclein Inclusions Elevate Dendritic Mitochondrial Oxidant Stress in Dopaminergic Neurons , 2013, The Journal of Neuroscience.

[11]  O. Hwang Role of Oxidative Stress in Parkinson's Disease , 2013, Experimental neurobiology.

[12]  S. Lukyanov,et al.  HyPer-3: a genetically encoded H(2)O(2) probe with improved performance for ratiometric and fluorescence lifetime imaging. , 2013, ACS chemical biology.

[13]  Christopher M. Dobson,et al.  Direct Observation of the Interconversion of Normal and Toxic Forms of α-Synuclein , 2012, Cell.

[14]  S. Gandhi,et al.  Mechanism of Oxidative Stress in Neurodegeneration , 2012, Oxidative medicine and cellular longevity.

[15]  Blaine R. Roberts,et al.  The hypoxia imaging agent CuII(atsm) is neuroprotective and improves motor and cognitive functions in multiple animal models of Parkinson’s disease , 2012, The Journal of experimental medicine.

[16]  Patrick A. Lewis,et al.  Parkinson's disease induced pluripotent stem cells with triplication of the α-synuclein locus , 2011, Nature communications.

[17]  M. Verbeek,et al.  Detection of elevated levels of α-synuclein oligomers in CSF from patients with Parkinson disease , 2011, Neurology.

[18]  Fred H. Gage,et al.  In vivo demonstration that α-synuclein oligomers are toxic , 2011, Proceedings of the National Academy of Sciences.

[19]  F. Marken,et al.  The synucleins are a family of redox-active copper binding proteins. , 2011, Biochemistry.

[20]  David R. Brown,et al.  Opus: University of Bath Online Publication Store Alpha-synuclein Is a Cellular Ferrireductase , 2022 .

[21]  J. Andersen,et al.  Mitochondrial alpha-synuclein accumulation impairs complex I function in dopaminergic neurons and results in increased mitophagy in vivo , 2010, Neuroscience Letters.

[22]  T. Tokuda,et al.  Detection of elevated levels of α-synuclein oligomers in CSF from patients with Parkinson disease , 2010, Neurology.

[23]  S. Gandhi,et al.  Dopamine Induces Ca2+ Signaling in Astrocytes through Reactive Oxygen Species Generated by Monoamine Oxidase , 2010, The Journal of Biological Chemistry.

[24]  V. Uversky,et al.  Metalloproteomics and metal toxicology of α-synuclein. , 2010, Metallomics : integrated biometal science.

[25]  J. Imlay,et al.  The iron-sulfur clusters of dehydratases are primary intracellular targets of copper toxicity , 2009, Proceedings of the National Academy of Sciences.

[26]  N. Avadhani,et al.  Mitochondrial Import and Accumulation of α-Synuclein Impair Complex I in Human Dopaminergic Neuronal Cultures and Parkinson Disease Brain* , 2008, Journal of Biological Chemistry.

[27]  J. Andersen,et al.  Increased murine neonatal iron intake results in Parkinson-like neurodegeneration with age , 2007, Neurobiology of Aging.

[28]  R. Tanzi,et al.  The 5′-untranslated region of Parkinson's disease α-synuclein messengerRNA contains a predicted iron responsive element , 2007, Molecular Psychiatry.

[29]  D. Sulzer,et al.  α-Synuclein Overexpression Increases Cytosolic Catecholamine Concentration , 2006, The Journal of Neuroscience.

[30]  C. Griesinger,et al.  Interaction of alpha-synuclein with divalent metal ions reveals key differences: a link between structure, binding specificity and fibrillation enhancement. , 2006, Journal of the American Chemical Society.

[31]  C. Dobson,et al.  Protein misfolding, functional amyloid, and human disease. , 2006, Annual review of biochemistry.

[32]  M. Duchen,et al.  Expression and Modulation of an NADPH Oxidase in Mammalian Astrocytes , 2005, The Journal of Neuroscience.

[33]  R. Hayward Stress , 2005, The Lancet.

[34]  B. Halliwell,et al.  Measuring reactive species and oxidative damage in vivo and in cell culture: how should you do it and what do the results mean? , 2004, British journal of pharmacology.

[35]  M. Duchen,et al.  β-Amyloid Peptides Induce Mitochondrial Dysfunction and Oxidative Stress in Astrocytes and Death of Neurons through Activation of NADPH Oxidase , 2004, The Journal of Neuroscience.

[36]  Janel O. Johnson,et al.  α-Synuclein Locus Triplication Causes Parkinson's Disease , 2003, Science.

[37]  Carl W. Cotman,et al.  Common Structure of Soluble Amyloid Oligomers Implies Common Mechanism of Pathogenesis , 2003, Science.

[38]  David R. Brown,et al.  Copper-dependent generation of hydrogen peroxide from the toxic prion protein fragment PrP106–126 , 2003, Neuroscience Letters.

[39]  A. Bush Metal complexing agents as therapies for Alzheimer’s disease , 2002, Neurobiology of Aging.

[40]  Robert Burke,et al.  Resistance of α-synuclein null mice to the parkinsonian neurotoxin MPTP , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[41]  P. Lansbury,et al.  Alpha-synuclein, especially the Parkinson's disease-associated mutants, forms pore-like annular and tubular protofibrils. , 2002, Journal of molecular biology.

[42]  V. Subramaniam,et al.  Dependence of α-synuclein aggregate morphology on solution conditions , 2002 .

[43]  C. Dobson,et al.  Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases , 2002, Nature.

[44]  P. Lansbury,et al.  Vesicle permeabilization by protofibrillar alpha-synuclein is sensitive to Parkinson's disease-linked mutations and occurs by a pore-like mechanism. , 2002, Biochemistry.

[45]  E. Junn,et al.  Human α-Synuclein over-expression increases intracellular reactive oxygen species levels and susceptibility to dopamine , 2002, Neuroscience Letters.

[46]  M. Duchen,et al.  Quantitative imaging of glutathione in hippocampal neurons and glia in culture using monochlorobimane , 2001, Journal of neuroscience research.

[47]  D. Allsop,et al.  Production of reactive oxygen species from aggregating proteins implicated in Alzheimer's disease, Parkinson's disease and other neurodegenerative diseases. , 2001, Current topics in medicinal chemistry.

[48]  H. Niznik,et al.  Direct binding and functional coupling of α‐synuclein to the dopamine transporters accelerate dopamine‐induced apoptosis , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[49]  H. Niznik,et al.  Direct binding and functional coupling of α-synuclein to the dopamine transporters accelerate dopamine-induced apoptosis. , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[50]  Sarah J. Tabrizi,et al.  Expression of mutant α-synuclein causes increased susceptibility to dopamine toxicity , 2000 .

[51]  T. Montine,et al.  Parkinson's disease is associated with oxidative damage to cytoplasmic DNA and RNA in substantia nigra neurons. , 1999, The American journal of pathology.

[52]  A J Lees,et al.  Pathological overlap in cases of parkinsonism associated with neurofibrillary tangles. A study of recent cases of postencephalitic parkinsonism and comparison with progressive supranuclear palsy and Guamanian parkinsonism-dementia complex. , 1993, Brain : a journal of neurology.

[53]  C. Marsden,et al.  Basal Lipid Peroxidation in Substantia Nigra Is Increased in Parkinson's Disease , 1989, Journal of neurochemistry.

[54]  C. Marsden,et al.  INCREASED NIGRAL IRON CONTENT IN POSTMORTEM PARKINSONIAN BRAIN , 1987, The Lancet.

[55]  Voon Wee Yong,et al.  Idiopathic Parkinson's disease, progressive supranuclear palsy and glutathione metabolism in the substantia nigra of patients , 1986, Neuroscience Letters.

[56]  N. Wood,et al.  PINK1 deficiency in b-cells increases basal insulin secretion and improves glucose tolerance in mice. , 2014, Open biology.

[57]  L. Defebvre,et al.  Targeting Chelatable Iron as a Therapeutic Modality in Parkinson ’ s Disease , 2016 .

[58]  I. Ferrer,et al.  Increased sensitivity to MPTP in human alpha-synuclein A30P transgenic mice. , 2006, Neurobiology of aging.

[59]  A. Singleton,et al.  alpha-Synuclein locus triplication causes Parkinson's disease. , 2003, Science.

[60]  V. Subramaniam,et al.  Dependence of alpha-synuclein aggregate morphology on solution conditions. , 2002, Journal of molecular biology.

[61]  S. Tabrizi,et al.  Expression of mutant alpha-synuclein causes increased susceptibility to dopamine toxicity. , 2000, Human molecular genetics.

[62]  G. Perry,et al.  Sequestration of iron by Lewy bodies in Parkinson’s disease , 2000, Acta Neuropathologica.